(Q56838141)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

New effective antituberculosis regimens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

Giovanni Battista Migliori

3 March 2020

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

18 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

9979

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

1703-1704

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Is tuberculosis elimination a reality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Measuring the effect of tuberculosis control: a step forward

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Rebalancing the global battle against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Tuberculosis: cost of illness in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962303-5

7 January 2021

10.1016/S0140-6736(14)62303-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795077%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference